Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M
Acrivon Therapeutics reported Q2 2026 results with a net loss of $18.0 million, beating estimates and narrowing YoY losses by 14.5%. R&D spend dropped due to non-recurring milestones, while G&A fell on lower compensation costs. The company holds $90.0 million in cash, funding operations through Q4 2027. Clinically, ACR-368 interim analysis is expected in H2 2026, and ACR-2316 enters dose expansion.
*this image is generated using AI for illustrative purposes only.
Acrivon Therapeutics (NASDAQ: ACRV) reported a quarterly loss of $(0.43) per share for the second quarter ended June 30, 2026, surpassing market expectations. The figure beat the analyst consensus estimate of $(0.50) by 14%, indicating tighter-than-expected cost management relative to forecasts.
Compared to the prior year, the company’s financial position showed marked improvement. The current quarter’s loss of $(0.43) per share represents a 21.82% reduction from the $(0.55) per share loss recorded in the same period last year. On an absolute basis, the net loss narrowed to $18.0 million from $21.0 million in Q2 2025.
Financial Performance
The improvement in the bottom line was driven by reduced operating expenses across both research and development (R&D) and general and administrative (G&A) categories.
Research and development expenses fell to $13.8 million in Q2 2026, down from $16.2 million in Q2 2025. This decrease was primarily attributed to two milestones achieved for the lead program ACR-368 in 2025 that did not recur in 2026, as well as the timing of other program progressions.
General and administrative expenses declined to $4.8 million from $6.5 million year-over-year. The reduction was driven by lower employee-related expenses, including stock-based compensation.
| Metric: | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net Loss: | $(17.96) million | $(21.01) million | -14.5% |
| EPS (Basic/Diluted): | $(0.43) | $(0.55) | -21.8% |
| R&D Expenses: | $13.8 million | $16.2 million | -14.8% |
| G&A Expenses: | $4.8 million | $6.5 million | -26.2% |
| Cash & Investments: | $90.0 million | N/A | N/A |
As of June 30, 2026, Acrivon held $90.0 million in cash, cash equivalents, and marketable securities. Management stated this liquidity position is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
Clinical Pipeline Updates
The financial results were accompanied by updates on the company’s precision medicine pipeline, leveraging its proprietary Generative Phosphoproteomics AP3 platform.
ACR-368: Dosing continues in both all-comer serous endometrial cancer (EC) arms (Arm 4 single agent and Arm 3 with ultra-low dose gemcitabine sensitization) in the registrational-intent Phase 2b study across US and European sites. A prespecified interim analysis is on track for the second half of 2026. Two presentations at the American Association for Cancer Research (AACR) Annual Meeting highlighted molecular mechanisms supporting potential combinations with immune checkpoint inhibitors (ICIs) or antibody-drug conjugates (ADCs).
ACR-2316: The Phase 1/2 trial advanced into the randomized dose expansion phase, evaluating 120 mg and 160 mg doses. The expansion assesses safety and activity in lung, endometrial, cervical, and esophago-gastric junction cancers. Data presented at AACR demonstrated strong synergy with ICIs, resulting in complete tumor regression with durable immune memory in preclinical models.
CDK11 Inhibitor Program: Internally discovered candidates from the AP3-driven cell cycle program are advancing in Investigational New Drug (IND)-enabling studies, showing complete regression in preclinical acute myeloid leukemia (AML) models.
What the Numbers Show
The data reveals a dual positive signal: operational performance exceeded immediate market expectations while demonstrating year-over-year progress. Beating the consensus estimate by 14% suggests that expense controls were more effective than anticipated by analysts, particularly given the absence of recurring milestone payments in R&D. Simultaneously, the 21.82% YoY narrowing of losses indicates a trajectory toward improved profitability, as the gap between revenue and expenses has significantly contracted compared to the previous fiscal year’s second quarter. The substantial cash reserve of $90.0 million provides a runway into late 2027, reducing near-term financing pressure as the company approaches key clinical data readouts for ACR-368.
How might the results of the prespecified interim analysis for ACR-368 in late 2026 influence the company's valuation and potential partnership opportunities?
Given the $90 million cash runway extending into Q4 2027, what is the likelihood of Acrivon requiring additional capital raises before completing its key Phase 2b trials?
Could the demonstrated synergy between ACR-2316 and immune checkpoint inhibitors lead to co-development deals with major pharmaceutical companies holding ICI franchises?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
